8-K: SmartKem Secures $9.1M, Addresses Nasdaq Delisting Threat

SmartKem, Inc. announced a private placement of convertible preferred stock and warrants, raising $9.1 million, and established an equity line of credit, which the company believes resolves its Nasdaq listing deficiency.

Summary

• SmartKem, Inc. entered into a Securities Purchase Agreement on March 30, 2026, for a private placement with institutional investors, including certain March Noteholders.
• The initial closing of the private placement involves the issuance of 11,411.5 shares of Series A Convertible Preferred Stock (stated value $1,000 per share, initial conversion price $0.5812 per share) and warrants to purchase up to 23,251,960 shares of Common Stock (initial exercise price $0.5812 per share).
• The gross proceeds from the private placement are expected to be $9,129,200, which includes the exchange of $3,750,000 in senior secured promissory notes (March Notes) at a 120% premium, totaling $4,500,000 in value.
• The company also entered into a Common Stock Purchase Agreement (Equity Line of Credit or ELOC) on March 30, 2026, allowing it to sell up to $500,000,000 of Common Stock to an investor at its discretion.
• Shares sold under the ELOC will be priced at 90% of the lesser of the lowest sale price or the volume-weighted average price (VWAP) during the applicable purchase period, with the investor's obligation capped at $5,000,000 per purchase.
• As consideration for the ELOC, SmartKem will issue 10,000 shares of Series A Preferred Stock to the ELOC investor.
• The company believes the private placement has increased its stockholders' equity to at least $2.5 million, addressing a Nasdaq Listing Rule 5550(b) deficiency for which it received a delisting notice on August 15, 2025.
• Stockholder approval is required for several actions, including increasing authorized Common Stock from 300,000,000 to 5,000,000,000, removing written consent restrictions, approving the issuance of all securities under the Preferred Stock Purchase Agreement, a reverse stock split, and increasing shares under the 2021 Equity Incentive Plan.
• The company is prohibited from issuing equity or equity-linked securities for 90 trading days after the registration statement's effectiveness (or Rule 144 eligibility), with certain exceptions.
• 25% of the gross proceeds from any ELOC sales will be used towards the redemption of the company's Series A Preferred Stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a necessary but costly financing. While it addresses immediate Nasdaq compliance and provides capital, the terms (deep discounts, high default dividend, significant dilution potential) indicate financial distress and a high cost of capital.

Positives

• Secured $9,129,200 in gross proceeds from the private placement, providing immediate capital.
• The company believes it has regained compliance with Nasdaq's $2.5 million stockholders' equity requirement, mitigating the immediate delisting threat.
• Established an Equity Line of Credit for up to $500,000,000, offering a flexible mechanism for future capital raises.
• The financing package addresses critical liquidity needs and provides a pathway to maintain public listing status.

Negatives

• The financing terms are highly dilutive, with Series A Preferred Stock convertible at $0.5812 per share and warrants exercisable at the same price, and ELOC shares sold at a 10% discount to market prices.
• The March Notes were exchanged at a 120% premium, reflecting a high cost of capital for prior debt.
• The Series A Preferred Stock carries a 15.0% per annum default dividend rate, indicating significant risk and potential future cash outflows.
• The requirement for stockholder approval for a substantial increase in authorized common stock and a reverse stock split suggests significant future dilution and potential stock price volatility.
• The ELOC investor receives 10,000 shares of Series A Preferred Stock as a commitment fee, further increasing the cost of capital.

Risks

• Ongoing risk of Nasdaq delisting if the company's next periodic report does not evidence sustained compliance with the $2.5 million stockholders' equity rule.
• Significant dilution to existing common stockholders from the conversion of Series A Preferred Stock, exercise of Warrants, and sales under the Equity Line of Credit.
• Failure to obtain required stockholder approvals for increasing authorized shares, removing written consent restrictions, or effecting a reverse stock split could hinder future financing or Nasdaq compliance efforts.
• The complex anti-dilution provisions and variable pricing mechanisms in the preferred stock and warrants could lead to unpredictable share issuances and further dilution.
• The company is prohibited from certain equity issuances and variable rate transactions for specified periods, limiting financial flexibility.

Future Outlook

The company expects to use the net proceeds from the private placement for working capital and general corporate purposes. It plans to seek stockholder approval for an increase in authorized common stock, removal of restrictions on written consent, compliance with Nasdaq rules for the issuance of securities, a reverse stock split, and an increase in shares under its 2021 Equity Incentive Plan. The company awaits Nasdaq's formal confirmation that it has regained compliance with the $2.5 million stockholders' equity requirement.

Management Comments

• The company believes it has stockholders' equity of at least $2.5 million as of the date of this Current Report on Form 8-K.
• The company awaits Nasdaq's formal confirmation that it has regained compliance with the Rule and will provide a further update when appropriate.

Industry Context

StockSavvy.ai notes that this type of complex financing, involving convertible preferred stock, warrants, and equity lines, is common for companies facing liquidity challenges or seeking to regain compliance with exchange listing standards. The deep discounts and anti-dilution provisions reflect the risk profile perceived by institutional investors in such situations, often indicating a high cost of capital for the issuer.

Comparison to Industry Standards

• StockSavvy.ai observes that the 30% original issue discount on the March Notes and the 10% discount on ELOC shares (90% of VWAP) are aggressive, indicating a high cost of capital for SmartKem compared to more financially stable companies.
• The 15.0% per annum default dividend rate on Series A Preferred Stock is significantly higher than typical preferred stock dividends for stable companies, reflecting elevated risk and investor demand for higher returns.
• The full ratchet anti-dilution protection on warrants is a strong investor protection feature, often seen in distressed or high-growth, early-stage companies where future dilutive financings are a significant concern, but less common for established, healthy public companies.

Corporate Governance

Related Party Transactions

• Certain institutional investors participating in the private placement are also March Noteholders, who are exchanging their previously issued senior secured promissory notes for Series A Preferred Stock and Warrants.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the conversion of Series A Preferred Stock, exercise of Warrants, and sales under the ELOC. The proposed reverse stock split, while aimed at Nasdaq compliance, could also impact per-share metrics and investor sentiment.
• **Institutional Investors (Buyers/Noteholders)**: Gain significant influence and protection through the terms of the Series A Preferred Stock (senior ranking, liquidation preference, anti-dilution, consent rights) and Warrants. They benefit from discounts on the securities and potential for high returns if the company's value recovers.
• **Employees/Management**: The increase in shares for the 2021 Equity Incentive Plan allows for continued equity-based compensation, which can be positive for retention and motivation.
• **Nasdaq**: The company is actively working to regain and maintain compliance with listing rules, which is positive for the integrity of the market and the company's continued trading on the exchange.

Next Steps

• The initial closing of the private placement is expected to take place on or about March 31, 2026.
• The company will file a registration statement for the resale of Common Stock issuable upon conversion of Series A Preferred Stock and exercise of Warrants no later than the tenth day following its annual report on Form 10-K for the year ended December 31, 2025.
• The company will use its reasonable best efforts to cause the registration statement to be declared effective by the SEC no later than 60 calendar days (or 120 days if subject to full SEC review) after the initial closing date.
• The company is required to seek stockholder approval for increasing authorized Common Stock, removing restrictions on written consent, approving the issuance of all securities under the Preferred Stock Purchase Agreement, a reverse stock split, and increasing shares under the 2021 Equity Incentive Plan, either by written consent within 45 days or at a meeting within 60 days of the initial closing date.
• The company is required to retain a consultant for strategic acquisitions and new business development within 30 days of the initial closing date.
• The company will file a registration statement for the resale of shares issuable under the ELOC Purchase Agreement no later than the tenth day following its annual report on Form 10-K for the year ended December 31, 2025.
• The company will confirm that an aggregate of 1,000,000,000 shares of Common Stock have been reserved for issuance under the ELOC Purchase Agreement within two business days following the increase in authorized shares of Common Stock contemplated by the Preferred Stock Stockholder Approval.
• The company awaits Nasdaq's formal confirmation that it has regained compliance with the $2.5 million stockholders' equity requirement.

Key Dates

Recommendation

The financing package addresses critical immediate concerns, including liquidity and Nasdaq listing compliance, which is a positive. However, the highly dilutive terms, significant discounts, and complex structure indicate underlying financial weakness and a high cost of capital. While the company has secured funding, the path to sustainable profitability and reduced dilution remains uncertain. Investors should hold and monitor execution of the business plan and future financial performance closely, especially regarding the impact of dilution and the outcome of stockholder approvals.

Keywords

SmartKem, SMTK, Private Placement, Series A Preferred Stock, Convertible Preferred Stock, Warrants, Equity Line of Credit, ELOC, Nasdaq Compliance, Delisting, Capital Raise, Dilution, Financial Restructuring, Corporate Governance